Treatment of kidney stone with Unani medicine Jawarish Zarooni Sada

Clinical validation of Unani pharmacopoeial formulation Jawarish Zarooni Sada in HasÄ?h al-Kulya (Nephrolithiasis)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/10/046645

Enrollment

110

Registered

2022-10-19

Start date

Unknown

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N200- Calculus of kidney

Interventions

Intervention1: Jawarish Zarooni Sada: 5gm orally to be taken orally twice daily with water after meals for 8 weeks Control Intervention1: NIl: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either gender in the age group 18-65 years. 2. Patients with HasÄ?h al-Kulya (Nephrolithiasis) as diagnosed by USG (KUB) with calculi measuring up to 5 mm (single or multiple) with or without any of the following symptoms: Pain or heaviness in flank region Pain or heaviness in groin/loin region Urinary urgency Nausea and vomiting

Exclusion criteria

Exclusion criteria: 1. Size of calculi above 5 mm 2. Patients with Renal colic and Hydronephrosis 3. Patients having impacted stones 4. Previous history of stone surgery 5. Patients with signs of renal failure 6. Pregnant and lactating women 7. Known cases of Hepatic, Renal or Cardiac ailments 8. Patients having systemic disease requiring long term treatment like Diabetes mellitus, Hypertension etc.

Design outcomes

Primary

Measure	Time frame
The efficacy of the drug will be assessed on the basis of following parameters: 1. Clinical Parameters i.e. Reduction in signs and symptoms. 2. Radiological Parameters- Ultrasound KUB will be taken as criteria for detection of reduction in stone size or expulsion of stone. 3. Frequency of Rescue medication used during the protocol duration. 4. Classical Examination of Urine (Nazri Muana-e-Bawl)Timepoint: At baseline, 2, 4, 6 and 8 weeks	—

Measure

Time frame

The efficacy of the drug will be assessed on the basis of following parameters: 1. Clinical Parameters i.e. Reduction in signs and symptoms. 2. Radiological Parameters- Ultrasound KUB will be taken as criteria for detection of reduction in stone size or expulsion of stone. 3. Frequency of Rescue medication used during the protocol duration. 4. Classical Examination of Urine (Nazri Muana-e-Bawl)Timepoint: At baseline, 2, 4, 6 and 8 weeks

—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: At baseline, 4 and 8 weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026